IRF7 and prostate cancer: IRF7 has been reported as the master regulator of type I IFN pathways and its involvement in IFN-β production has been well established.26,29 Higher expression of IRF7 and/or IFN-β is associated with a lower risk of bone metastasis in breast and prostate cancer,30,31 but the role of IRF7 in osteoclastogenesis, to our knowledge, has not been shown yet.